Stock Track | Henry Schein Plummets 5.01% as Q4 Earnings Disappoint, 2025 Guidance Cuts Amid Weak Demand

Stock Track

2025/02/25

Henry Schein Inc. (HSIC) shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.

The medical and dental products distributor reported adjusted earnings per share (EPS) of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected $3.27 billion, as higher prices squeezed customer budgets, forcing them to cancel or postpone non-urgent procedures.

For the full year 2025, Henry Schein forecasted adjusted EPS in the range of $4.80 to $4.94, below Wall Street's estimates of $4.99. The company also expects annual sales growth of only 2% to 4%, lower than the projected $13.19 billion, citing tepid demand amid persistent inflation in the dental and medical end-markets.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1139534195"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139534195\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139534195?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139534195","market":"us","top_or_hot":-1,"title":"Stock Track | Henry Schein Plummets 5.01% as Q4 Earnings Disappoint, 2025 Guidance Cuts Amid Weak Demand","media":"Stock Track","content":"<p>Henry Schein Inc. (HSIC) shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.</p>\n\n<p>The medical and dental products distributor reported adjusted earnings per share (EPS) of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected $3.27 billion, as higher prices squeezed customer budgets, forcing them to cancel or postpone non-urgent procedures.</p>\n\n<p>For the full year 2025, Henry Schein forecasted adjusted EPS in the range of $4.80 to $4.94, below Wall Street's estimates of $4.99. The company also expects annual sales growth of only 2% to 4%, lower than the projected $13.19 billion, citing tepid demand amid persistent inflation in the dental and medical end-markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Henry Schein Plummets 5.01% as Q4 Earnings Disappoint, 2025 Guidance Cuts Amid Weak Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Henry Schein Plummets 5.01% as Q4 Earnings Disappoint, 2025 Guidance Cuts Amid Weak Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Henry Schein Inc. (HSIC) shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.</p>\n\n<p>The medical and dental products distributor reported adjusted earnings per share (EPS) of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected $3.27 billion, as higher prices squeezed customer budgets, forcing them to cancel or postpone non-urgent procedures.</p>\n\n<p>For the full year 2025, Henry Schein forecasted adjusted EPS in the range of $4.80 to $4.94, below Wall Street's estimates of $4.99. The company also expects annual sales growth of only 2% to 4%, lower than the projected $13.19 billion, citing tepid demand amid persistent inflation in the dental and medical end-markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSIC","symbol_name":"汉瑞祥","start_time":0,"source_url":"","article_id":"1139534195","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139534195","pubTimestamp":1740496600,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Henry Schein Inc.  shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.The medical and dental products distributor reported adjusted earnings per share  of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSIC":"汉瑞祥"},"translate_title":"股票追踪Henry Schein暴跌5.01%，第四季度盈利令人失望，需求疲软导致2025年指引下调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSIC":1},"content_text":"Henry Schein Inc. (HSIC) shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.\nThe medical and dental products distributor reported adjusted earnings per share (EPS) of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected $3.27 billion, as higher prices squeezed customer budgets, forcing them to cancel or postpone non-urgent procedures.\nFor the full year 2025, Henry Schein forecasted adjusted EPS in the range of $4.80 to $4.94, below Wall Street's estimates of $4.99. The company also expects annual sales growth of only 2% to 4%, lower than the projected $13.19 billion, citing tepid demand amid persistent inflation in the dental and medical end-markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}